How safe is J&J’s Covid-19 single-shot vaccine? It is effective, according to the FDA, and has a “favorable safety profile.”


How safe is J&J’s Covid-19 single-shot vaccine? It is effective, according to the FDA, and has a “favorable safety profile.”

According to an investigation, Johnson & Johnson’s coronavirus vaccination is 85 percent effective in preventing severe instances of coronavirus.

After the US Food and Drug Administration (FDA) determined that Johnson & Johnson’s coronavirus vaccine was safe and effective against Covid-19, the vaccination is one step closer to reaching Americans. According to the research, vaccine efficacy against moderate to severe/critical coronavirus was 66.9% at least 14 days after the single-dose vaccination and 66.1 percent at least 28 days after vaccination across all geographic locations where the experiment was done.

The vaccine was 85.4 percent efficient at avoiding severe Covid-19 infections, according to the researchers. According to the FDA, the Johnson & Johnson vaccination has “recognized benefits” in terms of symptomatic and severe disease reduction. After Pfizer and Moderna, it could become the third Covid-19 vaccine to be approved for emergency use in the United States.

News from the Brinkwire

Why do Americans continue to be skeptical about the Covid-19 vaccine? Rural residents are among the most apprehensive about getting shots: Poll In the United States, how do allergic responses to the Covid-19 vaccine compare to those to flu shots? The CDC has a solution. “The safety analysis covered 43,783 randomized participants 18 years and older with a 2-month median follow-up to the data cutoff on January 22, 2021.” According to the 62-page study, “the analysis indicated a favorable safety profile, with no specific safety issues found that would limit issuance of an EUA.” “Analysis of secondary endpoints revealed vaccine effectiveness of 76.7 percent and 85.4 percent, respectively, against central laboratory-confirmed and blind-adjudicated severe/critical Covid-19 occurring at least 14 days and at least 28 days following vaccination,” it continues. Janssen Biotech, Inc. (the sponsor) requested an Emergency Use Authorization (EUA) from the FDA for the experimental vaccine Ad26.COV2.S on February 4, 2021. The Vaccines and Related Products Advisory Committee (VRBPAC) of the CDC will meet on February 26 to discuss the vaccine’s EUA for Americans aged 18 and up.

Depending on the outcome of a vote by the FDA’s vaccine advisory panel on Friday, the vaccine could be approved this week. By the end of March, the business stated it would be able to offer 20 million shots, with another 100 million doses available by the end of June.

A subgroup analysis of vaccination efficacy against moderate to severe/critical and severe/critical Covid-19 was done for the US, South Africa, and Brazil to see if the circulation of variant strains had an affect on vaccine efficacy. “Efficacy against moderate to severe/critical disease outcomes was shown to be lower in South Africa (52.0 percent and 64.0 percent, respectively) compared to the United States (74.4 percent and 72.0 percent, respectively) starting 14 days and 28 days following vaccination. Brinkwire News in a Nutshell


Comments are closed.